MAZURAKOVA, Alena, Lenka KOKLESOVA, Marek SAMEC, Erik KUDELA, Karol KAJO, Veronika SKUCIOVA, Sandra Hurta CSIZMAR, Veronika MESTANOVA, Martin PEC, Marian ADAMKOV, Raghad Khalid AL-ISHAQ, Karel ŠMEJKAL, Frank A GIORDANO, Dietrich BUSSELBERG, Kamil BIRINGER, Olga GOLUBNITSCHAJA and Peter KUBATKA. Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care. EPMA JOURNAL. Cham: SPRINGER INT PUBL AG, 2022, vol. 13, No 2, p. 315-334. ISSN 1878-5077. Available from: https://dx.doi.org/10.1007/s13167-022-00277-2.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care
Authors MAZURAKOVA, Alena, Lenka KOKLESOVA, Marek SAMEC, Erik KUDELA, Karol KAJO, Veronika SKUCIOVA, Sandra Hurta CSIZMAR, Veronika MESTANOVA, Martin PEC, Marian ADAMKOV, Raghad Khalid AL-ISHAQ, Karel ŠMEJKAL (203 Czech Republic, belonging to the institution), Frank A GIORDANO, Dietrich BUSSELBERG, Kamil BIRINGER, Olga GOLUBNITSCHAJA and Peter KUBATKA.
Edition EPMA JOURNAL, Cham, SPRINGER INT PUBL AG, 2022, 1878-5077.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.500
RIV identification code RIV/00216224:14160/22:00129768
Organization unit Faculty of Pharmacy
Doi http://dx.doi.org/10.1007/s13167-022-00277-2
UT WoS 000782529800001
Keywords in English Breast cancer; Phytochemicals; Individualized patient profiling; Modifiable risk factors; Health risk assessment; Molecular patterns; Predictive Preventive Personalized Medicine (PPPM/3PM); Primary secondary tertiary care; Treated cancer; COVID-19
Tags rivok, ÚPL
Tags International impact, Reviewed
Changed by Changed by: JUDr. Sabina Krejčiříková, učo 383857. Changed: 20/4/2023 17:05.
Abstract
Breast cancer incidence is actually the highest one among all cancers. Overall breast cancer management is associated with challenges considering risk assessment and predictive diagnostics, targeted prevention of metastatic disease, appropriate treatment options, and cost-effectiveness of approaches applied. Accumulated research evidence indicates promising anti-cancer effects of phytochemicals protecting cells against malignant transformation, inhibiting carcinogenesis and metastatic spread, supporting immune system and increasing effectiveness of conventional anti-cancer therapies, among others. Molecular and sub-/cellular mechanisms are highly complex affecting several pathways considered potent targets for advanced diagnostics and cost-effective treatments. Demonstrated anti-cancer affects, therefore, are clinically relevant for improving individual outcomes and might be applicable to the primary (protection against initial cancer development), secondary (protection against potential metastatic disease development), and tertiary (towards cascading complications) care. However, a detailed data analysis is essential to adapt treatment algorithms to individuals’ and patients’ needs. Consequently, advanced concepts of patient stratification, predictive diagnostics, targeted prevention, and treatments tailored to the individualized patient profile are instrumental for the cost-effective application of natural anti-cancer substances to improve overall breast cancer management benefiting affected individuals and the society at large.
PrintDisplayed: 2/9/2024 16:49